Cite
HARVARD Citation
Kantarjian, H. et al. (2018). Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Lancet. 5 (3), pp. e117-e126. [Online].